Chugai Pharma Taiwan wins 2021 Best Companies to Work for in Asia award for third year in a row
taipeitimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from taipeitimes.com Daily Mail and Mail on Sunday newspapers.
Chugai Pharmaceutical Co , Ltd : CHMP Recommends EU Approval of Chugai s Enspryng (Satralizumab) for Neuromyelitis Optica Spectrum Disorder (NMOSD)
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
CHMP Recommends EU Approval of Chugais Enspryng (Satralizumab) for Neuromyelitis Optica Spectrum Disorder (NMOSD)
financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.
Chugaiâs Enspryng becomes first approved medicine for NMOSD in Taiwan
Chugaiâs Enspryng becomes first approved medicine for NMOSD in Taiwan 11 December 2020 | News
Photo Credit: Freepik
Chugai Pharmaceutical Co., Ltd. announced that Chugai Pharma Taiwan Ltd., a wholly-owned subsidiary of Chugai, obtained an import drug license from the Taiwan Food and Drug Administration (TFDA) for Chugai’s Enspryng
® for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult and adolescent over 12 years old patients who are anti-aquaporin-4 (AQP4) antibody positive.
“Enspryng is the first approved product to apply our proprietary recycling antibody technology and the first NMOSD treatment targeting the IL-6 receptor. Chugai will cooperate with Chugai Pharma Taiwan so that Enspryng may be available to people with NMOSD in Taiwan as soon as possible.”